Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Brokers Set Expectations for Biohaven Pharmaceutical Holding Co Ltd’s Q1 2020 Earnings (NYSE:BHVN)

researchsnappy by researchsnappy
January 29, 2020
in Healthcare Research
0
Eric Aguiar Sells 3,537 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Biohaven Pharmaceutical logo

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Research analysts at Oppenheimer reduced their Q1 2020 earnings per share estimates for Biohaven Pharmaceutical in a report released on Thursday, January 23rd. Oppenheimer analyst E. Rajavelu now expects that the company will post earnings of ($2.12) per share for the quarter, down from their previous forecast of ($1.98). Oppenheimer has a “Buy” rating and a $67.00 price target on the stock. Oppenheimer also issued estimates for Biohaven Pharmaceutical’s Q2 2020 earnings at ($2.12) EPS, Q3 2020 earnings at ($2.12) EPS, Q4 2020 earnings at ($2.11) EPS, FY2020 earnings at ($8.47) EPS and FY2021 earnings at ($7.13) EPS.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Friday, November 1st. The company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.47).

Several other research firms have also commented on BHVN. Wedbush initiated coverage on Biohaven Pharmaceutical in a report on Thursday, December 12th. They set an “outperform” rating and a $75.00 price target on the stock. Cantor Fitzgerald lifted their price target on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, October 28th. Piper Jaffray Companies reiterated a “buy” rating and set a $100.00 price target on shares of Biohaven Pharmaceutical in a report on Monday, December 23rd. ValuEngine upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, December 7th. Finally, William Blair reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a report on Tuesday, December 10th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $72.25.

Shares of BHVN stock opened at $56.44 on Monday. The stock’s fifty day moving average is $54.30 and its two-hundred day moving average is $47.38. The firm has a market capitalization of $2.82 billion, a P/E ratio of -5.97 and a beta of 0.43. Biohaven Pharmaceutical has a fifty-two week low of $34.30 and a fifty-two week high of $67.86.

In related news, SVP Kimberly Gentile sold 3,935 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $53.03, for a total value of $208,673.05. Following the sale, the senior vice president now directly owns 3,935 shares in the company, valued at approximately $208,673.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Eric Aguiar sold 2,021 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $56.48, for a total transaction of $114,146.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 176,544 shares of company stock worth $9,506,726. Insiders own 23.90% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in Biohaven Pharmaceutical in the 4th quarter valued at about $122,000. California Public Employees Retirement System raised its holdings in Biohaven Pharmaceutical by 119.7% in the 4th quarter. California Public Employees Retirement System now owns 139,993 shares of the company’s stock valued at $7,621,000 after buying an additional 76,265 shares during the period. Columbus Circle Investors grew its position in Biohaven Pharmaceutical by 15.9% in the 4th quarter. Columbus Circle Investors now owns 23,593 shares of the company’s stock valued at $1,284,000 after acquiring an additional 3,235 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Biohaven Pharmaceutical by 30.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,405 shares of the company’s stock valued at $185,000 after acquiring an additional 787 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB acquired a new position in Biohaven Pharmaceutical in the 4th quarter valued at about $6,805,000. Hedge funds and other institutional investors own 92.46% of the company’s stock.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Recommended Story: How Investors Can Profit from Options Trading

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Radical Samsung Galaxy A51 launched to destroy the competition

Next Post

Greek shipowners urged to chase EU funding for low carbon ships

Next Post
Greek shipowners urged to chase EU funding for low carbon ships

Greek shipowners urged to chase EU funding for low carbon ships

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com